| 2343- | QC, | Pharmacological Activity of Quercetin: An Updated Review |
| - | Review, | Nor, | NA |
| 2300- | QC, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2303- | QC, | doxoR, | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2338- | QC, | Quercetin: A Flavonoid with Potential for Treating Acute Lung Injury |
| - | Review, | Nor, | NA |
| 2339- | QC, | Quercetin protects against LPS-induced lung injury in mice via SIRT1-mediated suppression of PKM2 nuclear accumulation |
| - | in-vivo, | Nor, | NA |
| 2340- | QC, | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
| - | in-vitro, | OS, | NA |
| 2341- | QC, | Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2342- | QC, | Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway |
| - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vivo, | NA, | NA |
| 2431- | QC, | The Protective Effect of Quercetin against the Cytotoxicity Induced by Fumonisin B1 in Sertoli Cells |
| - | in-vitro, | Nor, | TM4 |
| 2344- | QC, | Quercetin: A natural solution with the potential to combat liver fibrosis |
| - | Review, | Nor, | NA |
| - | Trial, | Nor, | NA |
| - | Trial, | HNSCC, | NA |
| 5971- | Rad, | CET, | Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck |
| - | Trial, | HNSCC, | NA |
| 156- | Ralox, | Tam, | GEN, | CUR, | Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 5286- | Ramu, | Ramucirumab efficacy in first-line gastric and esophageal cancer treatment |
| - | Review, | GC, | NA |
| 5268- | Ramu, | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) |
| - | Trial, | HCC, | NA |
| 5283- | Ramu, | Ramucirumab |
| - | Review, | Var, | NA |
| 5284- | Ramu, | https://pmc.ncbi.nlm.nih.gov/articles/PMC4131847/ |
| - | Review, | Var, | NA |
| - | Trial, | NSCLC, | NA |
| 5287- | Ramu, | Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study |
| - | in-vivo, | GC, | NA |
| 6056- | RES, | SeNPs, | A comparative study of resveratrol and resveratrol-functional selenium nanoparticles: Inhibiting amyloid β aggregation and reactive oxygen species formation properties |
| - | Study, | AD, | NA |
| 6051- | RES, | SeNPs, | Chit, | Resveratrol-loaded selenium/chitosan nano-flowers alleviate glucolipid metabolism disorder-associated cognitive impairment in Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 6054- | RES, | SeNPs, | Oral Administration of Resveratrol-Selenium-Peptide Nanocomposites Alleviates Alzheimer's Disease-like Pathogenesis by Inhibiting Aβ Aggregation and Regulating Gut Microbiota |
| - | in-vivo, | AD, | NA |
| 5857- | RES, | CAP, | Rad, | Resveratrol and capsaicin as safer radiosensitizers for colorectal cancer compared to 5-fluorouracil |
| - | in-vivo, | Var, | NA |
| 5781- | RES, | Resveratrol improves health and survival of mice on a high-calorie diet |
| - | in-vivo, | Nor, | NA |
| 5788- | RES, | Calorie restriction-like effects of 30 days of Resveratrol (resVida™) supplementation on energy metabolism and metabolic profile in obese humans |
| - | Trial, | Nor, | NA |
| 5797- | RES, | Enhancing the Delivery of Resveratrol in Humans: If Low Bioavailability is the Problem, What is the Solution? |
| - | Review, | Nor, | NA |
| 2333- | RES, | Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells |
| - | in-vitro, | Nor, | NA |
| 2334- | RES, | Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy |
| - | Review, | Var, | NA |
| 2332- | RES, | Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism |
| - | Review, | Var, | NA |
| 2331- | RES, | Resveratrol improves follicular development of PCOS rats via regulating glycolysis pathway and targeting SIRT1 |
| - | in-vivo, | Nor, | NA |
| 2330- | RES, | Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF7 |
| 2329- | RES, | Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis |
| - | in-vitro, | Melanoma, | A375 |
| 2328- | RES, | Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 |
| 2650- | RES, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2687- | RES, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 3085- | RES, | Resveratrol interrupts Wnt/β-catenin signalling in cervical cancer by activating ten-eleven translocation 5-methylcytosine dioxygenase 1 |
| - | in-vitro, | Cerv, | NA |
| 3084- | RES, | Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D |
| 3083- | RES, | Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 3082- | RES, | Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 3081- | RES, | Resveratrol and p53: How are they involved in CRC plasticity and apoptosis? |
| - | Review, | CRC, | NA |
| 3080- | RES, | Resveratrol: A miraculous natural compound for diseases treatment |
| - | Review, | Var, | NA |
| 3079- | RES, | Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action |
| - | Review, | Var, | NA |
| 3078- | RES, | The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment |
| - | Review, | Pca, | NA |
| 3077- | RES, | Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways |
| - | in-vitro, | Chon, | HTB94 |
| 3076- | RES, | Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells |
| - | Review, | Var, | NA |
| 3075- | RES, | Rad, | The Protection Effect of Resveratrol Against Radiation-Induced Inflammatory Bowel Disease via NLRP-3 Inflammasome Repression in Mice |
| - | in-vivo, | Nor, | NA |
| 3074- | RES, | Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer |
| - | Review, | BC, | NA |
| 3098- | RES, | Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers |
| - | Review, | Var, | NA |
| 3073- | RES, | Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy |
| - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid